A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements

Johnny W. Huang1,2, Brianna Lahey2,3, Owen J. Clarkin4, Jennifer Kong3, Edward Clark1,2,3, Salmaan Kanji1,3, Christopher McCudden1,2, Ayub Akbari1,2,3, Benjamin J.W. Chow4, Wael Shabana1,2,3 and Swapnil Hiremath1,2,3

1The Ottawa Hospital, Ottawa, Ontario, Canada; 2University of Ottawa, Ottawa, Ontario, Canada; 3Division of Nephrology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; and 4University of Ottawa Heart Institute, Ottawa, Ontario, Canada

Introduction: N-acetylcysteine (NAC) is an antioxidant that can regenerate glutathione and is primarily used for acetaminophen overdose. NAC has been tested and used for preventing iatrogenic acute kidney injury or slowing the progression of chronic kidney disease, with mixed results. There are conflicting reports that NAC may artificially lower measured serum creatinine without improving kidney function, potentially by assay interference. Given these mixed results, we conducted a systematic review of the literature to determine whether there is an effect of NAC on kidney function as measured with serum creatinine and cystatin C.

Methods: A literature search was conducted to identify all study types reporting a change in serum creatinine after NAC administration. The primary outcome was change in serum creatinine after NAC administration. The secondary outcome was a change in cystatin C after NAC administration. Subgroup analyses were conducted to assess effect of creatinine assay (Jaffe vs. non-Jaffe and intravenous vs. oral).

Results: Six studies with a total of 199 participants were eligible for the systematic review and meta-analysis. There was a small but significant decrease in serum creatinine after NAC administration overall (weighted mean difference [WMD], −2.80 µmol/L [95% confidence interval (CI) −5.6 to 0.0]; P = 0.05). This was greater with non-Jaffe methods (WMD, −3.24 µmol/L [95% CI −6.29 to −0.28]; P = 0.04) than Jaffe (WMD, −0.51 µmol/L [95% CI −7.56 to 6.53]; P = 0.89) and in particular with intravenous (WMD, −31.10 µmol/L [95% CI −58.37 to −3.83]; P = 0.03) compared with oral NAC (WMD, −2.5 µmol/L [95% CI −5.32 to 0.32]; P = 0.08). There was no change in cystatin C after NAC administration.

Discussion: NAC causes a decrease in serum creatinine but not in cystatin C, suggesting analytic interference rather than an effect on kidney function. Supporting this, the effect was greater with non-Jaffe methods of creatinine estimation. Future studies of NAC should use the Jaffe method of creatinine estimation when kidney outcomes are being reported. Even in clinical settings, the use of an enzymatic assay when high doses of intravenous NAC are being used may result in underdiagnosis or delayed diagnosis of acute kidney injury.

Kidney Int Rep (2021) 6, 396–403; https://doi.org/10.1016/j.ekir.2020.11.018
KEYWORDS: acute kidney injury; assay interference; N-acetylcysteine; serum creatinine; serum cystatin C
© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

N-acetylcysteine (NAC) is an antioxidant that can regenerate glutathione and is primarily used for acetaminophen overdose.1 It has also been tested in prevention of acute kidney injury (AKI) in different settings, such as postoperative AKI and contrast-induced AKI (CI-AKI) with mixed results, mainly using change in serum creatinine levels before and after NAC treatment as the outcome. The larger subsequent trials conducted with clinical outcomes have not shown any benefit, but the reason for the discrepancy between earlier trials that showed a benefit in serum creatinine levels and these subsequent trials has not been clearly established.2-4 Given the low cost and lack of side effects, NAC has been recommended for use by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.5 Similarly, a systematic review from the Agency for Healthcare Research and Quality also supports its use for CI-AKI prophylaxis.6 At

Correspondence: Swapnil Hiremath, The Ottawa Hospital, Riverside Campus, 1967 Riverside Dr, Ottawa, Ontario, Canada K1H 7W9. E-mail: shiremath@toh.ca
Received 8 June 2020; revised 3 November 2020; accepted 17 November 2020; published online 3 December 2020

396 Kidney International Reports (2021) 6, 396–403
Clinical Research

Views and Meta-Analysis Statement.14 A comprehensive literature search was conducted using electronic databases including MEDLINE, Embase, and the Cochrane Central Library. In consultation with an information scientist, databases were searched in all available time, from the oldest literature to the search date (i.e., 1947 to October 2018; Supplementary Table S1). Bibliographies and citations of published works were cross-referenced for additional potential studies. To minimize the potential for English-only language bias, manuscripts written in other languages encountered via cross-checking for relevance were also considered.

Inclusion and Exclusion Criteria
All studies that explored the potential effect of NAC on kidney function as quantified by baseline and follow-up serum creatinine, serum cystatin C, and/or glomerular filtration rate (GFR) measurements were considered for screening. There were no limitations by population, study design, date, or language. The study participants were ≥18 years of age and were receiving NAC with previous and subsequent serum measurement of creatinine, cystatin C, and/or GFR. Exclusion criteria included patients with minimal to no kidney function such as in end-stage kidney disease. Patient populations receiving contrast agents and those simultaneously undergoing surgery were excluded from the study to avoid potential for confounding because of CI-AKI or other causes of AKI. Existing systematic reviews and meta-analyses were excluded, but their bibliographies and more recently cited articles were cross-referenced to augment the literature search.

Study Selection
Pertinent articles identified by our search strategy were reviewed systematically in duplicate. Abstracts were screened independently by 2 authors (BL, OJC, or JWH), and studies that met exclusion criteria were excluded in the first-round of analysis. Articles that were not excluded outright via abstract analysis were reviewed as full-text documents and subject to full review (by BL, OJC, or JWH) for inclusion/exclusion criteria. All disagreement regarding article inclusion was resolved by an in-person meeting for consensus and forwarded to another reviewer (SH) for adjudication.

Data Collection Process
A data extraction template was developed by the principal investigator (SH) and modified by feedback from 2 independent reviewers (OJC and JWH) to ensure that complete data were obtained. OJC and JWH performed data extraction from selected manuscripts and compared for consistency. In cases with disagreement, consensus was attempted via further discussion, and input by a third reviewer (SH) if necessary. Reviewers were not blinded to the authors or journals during this process.

The following information was extracted from all included studies: research group, country of origin, year of publication, funding source, study design, patient population (i.e., healthy volunteers vs. patients with CKD, sample size, sex, age, presence of other comorbid conditions such as diabetes), NAC details (i.e., route of administration, dose, and frequency), and control group (placebo-controlled vs. no treatment).

Methods

Search Strategy
The protocol for this systematic review was registered in PROSPERO (registration no. CRD42017055984) and has been published.13 This review is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.14 A comprehensive literature search was conducted using electronic databases including MEDLINE, Embase, and the Cochrane Central Library. In consultation with an information scientist, databases were searched in all available time, from the oldest literature to the search date (i.e., 1947 to October 2018; Supplementary Table S1). Bibliographies and citations of published works were cross-referenced for additional potential studies. To minimize the potential for English-only language bias, manuscripts written in other languages encountered via cross-checking for relevance were also considered.
**Subgroup Analyses and Metaregression**

With regard to meta-bias assessment, univariate meta-regression analyses were conducted to assess the effects of clinical factors (e.g., dose of NAC) on the meta-analysis estimates, when applicable. Subgroup analyses were conducted based on route of NAC (oral vs. intravenous [i.v.]), method of creatinine measurement (Jaffe vs. non-Jaffe methods), and study population (CKD vs. healthy volunteers). Funnel plot methodology, using visualization of the asymmetry and the Egger statistic, were used to identify publication bias.¹⁹

**Change in Serum Creatinine**

Meta-analyses of the 6 studies are presented in Figure 2. All studies showed a varying degree (i.e., ranging from −0.35 to −31.1 µmol/l) of reduced serum creatinine change after NAC dosing with respect to the baseline measurement. The WMD was −2.80 µmol/l [95% confidence interval [CI], −5.6 to 0.0; P = 0.05], suggesting a small, statistically significant decrease in serum creatinine after NAC. The heterogeneity was not statistically significant, with a Cochran Q of 4.7 (P = 0.45).

**Subgroup Analyses and Metaregression**

Subgroup analyses was performed to compare the 6 included studies that used different serum creatinine determination methodology, study population, and route of NAC administration (Table 2). The decrease in serum creatinine was statistically significant with the non-Jaffe method (−3.24 µmol/l [95% CI, −6.29 to −0.18]; P = 0.04) compared with the Jaffe method (−0.51 µmol/l [95% CI, −7.56 to 6.53]; P = 0.89). There

---

**RESULTS**

**Study Selection**

The literature search identified 628 articles collectively from MEDLINE, Embase, and the Cochrane Central Library, citation tracking, and gray literature search. Five hundred seventy-eight articles were excluded after primary screening based on title and abstract. A full-text review of the remaining 50 articles resulted in the further exclusion of 43 articles, primarily because
also was a greater decrease in serum creatinine with the route of i.v. NAC (−31.10 μmol/l [95% CI, −58.37 to −3.83]; P = 0.03) compared with oral NAC (−2.5 μmol/l [95% CI, −5.32 to 0.32]; P = 0.08). The univariable metaregression analysis did not show a significant effect of NAC dose, baseline creatinine, or other demographic characteristics studied on mean serum creatinine.

Change in Cystatin C

Meta-analyses of the 4 studies that reported pre- and post-NAC serum cystatin C change are presented in Figure 3. No changes were demonstrated in cystatin C change post–NAC dosing with respect to the baseline measurement, with a WMD of −0.84 μmol/l (95% CI, −3.14 to 1.47; P = 0.48). Heterogeneity for NAC and cystatin C was not significant (Cochran Q = 0.13, I² = 0; P = 0.99).

Publication Bias

There was evidence of publication bias by visual examination of the funnel plot for the outcome of serum creatinine (Figure 4). One study was imputed which changes the pooled WMD estimate to −2.50 μmol/l (95% CI, −5.29 to 0.29; Figure 4). The Egger regression intercept was not significant (P = 0.32). There was no

Table 1. Study characteristics of the included studies and route, dose, and regimen of NAC

| Study | Country       | Year  | Study design       | Setting/population | Dose and regimen | Sample size, n | Men, % | Mean age, yrs | Patients with diabetes, % | Follow-up               |
|-------|---------------|-------|--------------------|--------------------|------------------|----------------|--------|---------------|--------------------------|------------------------|
| Hoffmann et al.⁹ | Germany       | 2004  | Before/after single arm | Healthy volunteers | 4 doses of oral NAC (each 600 mg) at 12-hr intervals for 2 days | 50              | 48     | 32.8          | N/A                      | 48 hrs after last NAC |
| Mainra et al.⁰² | Canada        | 2007  | Before/after single arm | Patients with CKD  | 1 dose of oral NAC (600 mg) for 1 day | 30              | 83.3   | 66            | N/A                      | 48 hrs after last NAC |
| Moist et al.¹⁰ | Canada        | 2010  | Double blind, randomized controlled trial | Patients with CKD | 4 doses of oral NAC (each 1200 mg) at 12-hr intervals for 2 days | 60              | 76.7   | 68.6          | 50                       | 48 hrs after last NAC |
| Rehman et al.²¹ | US            | 2008  | Before/after single arm | Patients with CKD | 4 doses of oral NAC (each 1200 mg) at 12-hr intervals for 2 days | 30              | 60     | 65.3          | 38                       | 48 hrs after last NAC |
| Renke et al.²² | Poland        | 2010  | Placebo and randomized controlled | Patients with CKD | 2 doses of oral NAC (each 1200 mg) per day for 8 weeks | 20              | 60     | 39.4          | 0                        | N/A                    |
| Sochman and Krizova²³ | Czech Republic | 2006  | Before/after single arm | Patients with CKD | 1 dose of i.v. NAC (100 mg) for 1 day | 10              | 70     | 71            | 10                       | 24 hrs after last NAC |

CKD, chronic kidney disease; i.v., intravenous; N/A, not available; NAC, N-acetylcysteine; US, United States.
evidence of publication bias both by visual examination or the Egger test for the analysis of NAC and cystatin C.

**Quality Assessment**

Table 3 presents the Newcastle-Ottawa Scale quality assessment scores of the 6 included studies. Overall, 1 study achieved a total score of 8 (out of 9), 4 studies scored 5 points, and 1 study scored 4. In terms of selection, all but 1 study incorporated the before/after single-arm design, and therefore did not include a matched control group for comparison. All studies used secure medical records for ascertainment of exposure. In terms of comparability, 5 studies did not report adjustment for potential confounding variables in their respective methodologies. The lone study with a matched control group showed statistical comparisons of baseline characteristics. In terms of outcome, 4 studies received a score of 2 for appropriate assessment of outcome and an adequate proportion of patients with follow-up. Finally, 5 studies lost a point for short duration of follow-up (e.g., 48 hours after last dose of NAC).

**DISCUSSION**

This systematic review was conducted to determine the effect on kidney function, namely serum creatinine and cystatin C, while excluding studies in the setting of contrast administration and patients undergoing surgeries/procedures to avoid confounding caused by concomitant AKI. This study identified 6 prospective studies, with the pooled estimate of a small but statistically significant effect of NAC on lowering serum creatinine of $-2.8 \text{ mmol/l}$. Moreover, on subgroup analysis, the effect was greater when pooling the studies that did not use the Jaffe method of creatinine estimation. In addition, i.v. NAC also resulted in a greater lowering of serum creatinine than oral NAC. In contrast, there was no effect of NAC on cystatin C measurement. This implies that the effect of NAC on serum creatinine is a result of analytic interference and was greater with the enzymatic assay compared with the Jaffe method.

These findings support the initial report from Hoffman et al., which suggested that NAC causes a change in serum creatinine without truly having an effect on kidney function. In vitro analysis does suggest that at extremely high concentration, NAC may interfere with the enzymatic assay, causing a falsely lower serum creatinine. The concentration of NAC achieved in the serum with oral administration of NAC, as is done in clinical trials, rarely achieves these high concentrations. However, this concentration will be achieved with i.v. NAC administration, which is coherent with the analysis from the present study showing a greater effect ($-31 \text{ mmol/l}$) with i.v. NAV compared with oral ($-2.5 \text{ mmol/l}$). In addition, though the decrease in serum creatinine with oral NAC does not seem clinically significant, it may still result in a difference in CI-AKI events with NAC compared with placebo if these are only measured in terms of change in creatinine. This may explain the discrepancy between the beneficial effect of NAC as reported in some trials but not others. More specifically, this finding—that the effect of NAC is an artifact of assay interference—explains the null finding of more recent large clinical trials of NAC.

**Table 2. Subgroup analysis of Jaffe vs. non-Jaffe, oral vs. i.v., and CKD vs. non-CKD**

| Study subgroups | Weighted mean difference (95% CI) | P value |
|-----------------|----------------------------------|---------|
| Method of creatinine measurement |                                    |         |
| Jaffe           | $-0.51 (-7.56 to 6.53)$           | 0.89    |
| Non-Jaffe       | $-3.24 (-6.29 to -0.18)$          | 0.04    |
| NAC route       |                                    |         |
| Oral            | $-2.50 (-5.32 to 0.32)$           | 0.82    |
| i.v.            | $-3.10 (-5.87 to -3.38)$          | 0.03    |
| Study population|                                    |         |
| CKD             | $-3.19 (-8.44 to 2.07)$           | 0.24    |
| Non-CKD         | $-2.65 (-5.97 to 0.66)$           | 0.12    |

CKD, chronic kidney disease; i.v., intravenous; NAC, N-acetylcysteine.
One may wonder about the clinical significance of these findings, given that the most recent large RCTs have shown clearly that NAC has no benefit in the setting of CI-AKI. However, NAC is still being studied in other settings, with 30 ongoing trials to prevent AKI and the progression of CKD. It is important that serum creatinine measurement be performed in these trials with an assay (such as the Jaffe method) that does not interfere with NAC administration. Alternately, the investigators could validate the creatinine measurements using both enzymatic and Jaffe methods in a subset of participants both before and after NAC administration. This consideration is especially valid with i.v. NAC administration. The effect reported in the present study was strongest with high doses of NAC administered. Oral NAC has poor oral bioavailability, so the higher effect seen with i.v. NAC may reflect greater serum NAC concentrations and subsequent interference. High doses of i.v. NAC are used in the setting of acetaminophen overdose and in patients with alcoholic hepatitis. A falsely low serum creatinine, when measured with the enzymatic assay, may mask the development of AKI in this clinical setting.

The change in serum creatinine with i.v. NAC was $-31 \mu$mol/l, which is certain to result in a significant difference in AKI count in any trial if using the Kidney Disease: Improving Global Outcomes staging (stage 1 being 26.5 $\mu$mol/l). This will also likely result in the underdiagnosis or delayed of clinically significant AKI occurrence in these settings of i.v. NAC use, which is typically used as an antidote.

This systematic review has certain limitations. The sample size of the individual studies was small, but that is typical for mechanistic studies of this nature. The change in creatinine was small but statistically significant and contrasts with the lack of change in cystatin C. There is publication bias, with the imputation of a study shifting the pooled estimate to the null. Lastly, the overall quality of the studies included was not high.

In conclusion, the systematic review reports a small but significant decrease in serum creatinine with NAC administration but not in cystatin C. This effect seems to be higher when creatinine is measured with the enzymatic assay and with i.v. NAC administration.
Table 3. Newcastle-Ottawa quality assessment score of the 6 studies

| Study                  | Year | Selection | Comparability | Outcome | Total score |
|------------------------|------|-----------|---------------|---------|-------------|
| Hoffmann et al.9       | 2004 | ***       |               |         |             |
| Mainra et al.20        | 2007 | ***       |               |         |             |
| Moir et al.10          | 2010 | ****      | *             |         |             |
| Rehman et al.22        | 2008 | ***       |               |         |             |
| Renke et al.22         | 2010 | ***       |               |         |             |
| Sochman and Krizova23  | 2006 | ***       |               |         |             |

The * represent the quality of the study by each domain mentioned in the column. More * refers to higher quality and absence of * or less * denote a lower quality. See ‘quality assessment’ section in methods for details.

DISCLOSURE

BC has a potential competing interest with CV Diagnostix, AusculSciences, and Toronto-Dominion Bank. The other authors declared no competing interests.

ACKNOWLEDGMENTS

We acknowledge the institutional support of the Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada. SH and EC receive research salary support from the Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

AUTHOR CONTRIBUTIONS

SH, AA, and CM did the initial design. SH, JWH, OJC, BL, and JK wrote the manuscript. All authors read and approved the final manuscript.

SUPPLEMENTARY MATERIAL

Supplementary File (PDF)
Table S1. Details of literature search strategy. PRISMA Checklist.

REFERENCES

1. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359:285–292.
2. Weisbord SD. Kidney biopsy in hospitalized patients with acute kidney disease: is there an increased risk? Clin J Am Soc Nephrol. 2018;13:1617–1618.
3. Berwanger O, Cavalcanti AB, Sousa AM, et al. Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a substudy of the acetylcysteine for contrast-induced nephropathy trial. Circ Cardiovasc Interv. 2013;6:139–145.
4. Gonzales DA, Norsworthy JK, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007;5:32.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
6. Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:406–416.
7. Sandilands EA, Cameron S, Paterson F, et al. Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-contrast agent: study protocol. BMC Clin Pharmacol. 2012;12:3.
8. Nolin TD, Ouseph R, Himmelfarb J, McNenamin ME, Ward RA. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol. 2010;5:1588–1594.
9. Hoffmann U, Fischereider M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol. 2004;15:407–410.
10. Moir L, Sontrop JM, Gallo K, et al. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial. Am J Kidney Dis. 2010;56:643–650.
11. Greenwald I. The chemistry of Jaffe’s reaction for creatinine II. The effect of substitution in the creatinine molecule and a possible formula for the red tautomer1. J Am Chem Soc. 1925;47:1443–1448.
12. Panteghini M. Enzymatic assays for creatinine: time for action. Scand J Clin Lab Invest Suppl. 2008;241:84–88.
13. Huang JW, Clarkin OJ, McCudden C, et al. The effect of N-acetylcysteine on creatinine measurement: protocol for a systematic review. Can J Kidney Health Dis. 2018;5, 205438118801017.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
16. Wells G, Shea B, O’Connell D, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Available at: http://www.evidencebasedpublichealth.de/download/Newcastle_Ottawa_Scale_Pope_Bruce.pdf. Accessed December 9, 2020.
17. Penson DF, Krishnaswami S, Jules A, et al. Evaluation and Treatment of Cryptorchidism. Comparative Effectiveness Reviews, No. 88. Appendix E. Available at: https://www.ncbi.nlm.nih.gov/books/NBK115843/bin/appe-fm3.pdf. Accessed December 9, 2020.
18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
20. Mainra R, Gallo K, Moist L. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease. Nephrology (Carlton). 2007;12:510–513.
21. Rehman T, Fought J, Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol. 2008;3:1610–1614.
22. Renke M, Tyllicki L, Rutkowski P, et al. The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-
controlled, randomized, open, cross-over study. Kidney Blood Press Res. 2008;31:404–410.

23. Sochman J, Krizova B. Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy. Kardiol Pol. 2006;64:559–564.

24. Lognard M, Cavalier E, Chapelle JP, Lambermont B, Krzesinski JM, Delanaye P. Acetylcysteine and enzymatic creatinine: beware of laboratory artefact!. Intensive Care Med. 2008;34:973–974.

25. Acetylcysteine for Contrast-induced Nephropathy Trial Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250–1259.

26. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378:603–614.

27. Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. Trials. 2009;10:45.